Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su Vedolizumab con Tofacitinib negli adulti affetti da colite ulcerosa (UC)

22 ottobre 2026 aggiornato da: Takeda

Uno studio multicentrico di fase 4, in aperto, a braccio singolo, per valutare l’induzione della risposta e la remissione della terapia a doppio bersaglio con Vedolizumab e tofacitinib in pazienti adulti affetti da colite ulcerosa attiva da moderatamente a grave

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with vedolizumab alone after the double treatment.

All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks.

Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Descrizione dettagliata

The drugs being tested in this study are called Vedolizumab and Tofacitinib. Vedolizumab and Tofacitinib dual targeted therapy is being tested to treat people with moderate to severe UC who have experienced inadequate response, loss of response or intolerance to no more than 2 prior tumor necrosis factor (TNF) antagonists. This study will look at the clinical remission in people who take Vedolizumab and Tofacitinib dual targeted therapy.

The study will enroll approximately 60 participants. All the participants will be enrolled in a single treatment group to receive dual targeted treatment with Vedolizumab and Tofacitinib for the first 8 weeks:

Vedolizumab 300 mg + Tofacitinib 10 mg

Only those participants who show a clinical response at Week 8 will transition to Vedolizumab monotherapy for 44 weeks.

This multi-center trial will be conducted in the United States and Canada. The overall duration of the study is up to 76 weeks. Participants will be followed up for 26 weeks after the last dose of the study drug for safety.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Ontario
      • Barrie, Ontario, Canada, L4M 7G1
        • Barrie GI Associates Inc.
      • London, Ontario, Canada, N6A 5A5
        • London Health Sciences Centre
      • Mississauga, Ontario, Canada, L5M 7N4
        • West GTA Endoscopy Inc.
      • North Bay, Ontario, Canada, P1B 2H3
        • Viable Clinical Research - North Bay
      • North York, Ontario, Canada, M6A3B4
        • Toronto Immune and Digestive Health Institute Inc. (TIDHI)
      • Oakville, Ontario, Canada, L6L 5L7
        • ABP Research Services Corp.
      • Oshawa, Ontario, Canada, L1J 0C7
        • Taunton Surgical Centre
      • Vaughan, Ontario, Canada, L4L 4Y7
        • Toronto Digestive Disease Associates (TDDA) Inc.
    • Quebec
      • Montreal, Quebec, Canada, H3G 1A4
        • The Research Institute of the McGill University Health Centre
    • Alabama
      • Dothan, Alabama, Stati Uniti, 36301
        • Digestive Health Specialsits
    • Arizona
      • Sun City, Arizona, Stati Uniti, 85351
        • GI Alliance Sun City
    • California
      • Los Angeles, California, Stati Uniti, 90048
        • Cedars-Sinai Medical Center
      • Newport Beach, California, Stati Uniti, 92663
        • Hoag Hospital Newport Beach
    • Florida
      • Orlando, Florida, Stati Uniti, 32803
        • Endoscopic Research Inc
      • Tampa, Florida, Stati Uniti, 33615
        • Alliance Clinical Research of Tampa, LLC
    • Georgia
      • Roswell, Georgia, Stati Uniti, 30076
        • Gastroenterology Consultants, P.C.
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • University of Chicago Medicine
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • University of Kansas Medical Center
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40202
        • University of Louisville
    • Louisiana
      • Metairie, Louisiana, Stati Uniti, 70006
        • GI Alliance
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Tulane University
    • Maryland
      • Chevy Chase, Maryland, Stati Uniti, 20815
        • Capital Digestive Care - MGG Group - Chevy Chase Clinical Research
    • Michigan
      • Ypsilanti, Michigan, Stati Uniti, 48197
        • Huron Gastroenterology Associates, P.C.
    • Minnesota
      • Plymouth, Minnesota, Stati Uniti, 55446
        • MNGI Digestive Health, PA
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64111
        • Mid-America Gastro-Intestinal Consultants
      • Liberty, Missouri, Stati Uniti, 64068
        • BVL Clinical Research
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, Stati Uniti, 10016
        • NYU Langone Health
      • New York, New York, Stati Uniti, 10065
        • Weill Cornell Medical College- New York Presbyterian Hospital
    • North Carolina
      • Asheville, North Carolina, Stati Uniti, 28801
        • Digestive Health Partners
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • University of North Carolina
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45627
        • University of Cincinnati
      • Columbus, Ohio, Stati Uniti, 43202
        • Ohio Gastroenterology group, Inc.
      • Westlake, Ohio, Stati Uniti, 44145
        • Gastro Intestinal Research Institute of Northern Ohio, LLC.
    • Pennsylvania
      • Wexford, Pennsylvania, Stati Uniti, 15090
        • Allegheny Health Network
    • Rhode Island
      • Providence, Rhode Island, Stati Uniti, 02094
        • University Gastroenterology
    • South Dakota
      • Rapid City, South Dakota, Stati Uniti, 57701
        • Sanford Health Research
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • The University of Texas Health Science Center at Houston
      • Mansfield, Texas, Stati Uniti, 76063
        • GI Alliance - Mansfield
      • San Antonio, Texas, Stati Uniti, 78229
        • Gastroenterology Research of San Antonio, LLC
      • Southlake, Texas, Stati Uniti, 76092
        • Texas Digestive Disease Consultants (TDDC), Southlake
      • Tyler, Texas, Stati Uniti, 75701
        • Tyler Research Institute, LLC
      • Webster, Texas, Stati Uniti, 77598
        • GI Alliance - Webster
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84108
        • University of Utah Health
    • Washington
      • Tacoma, Washington, Stati Uniti, 98405
        • Washington Gastroenterology- GIA

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Has a confirmed diagnosis of UC established at least 3 months prior to screening, by clinical and endoscopic evidence and corroborated by a histopathology report.
  2. Has moderately to severely active UC as determined by a complete Mayo score [including PGA] of 6 to 12 with a rectal bleeding subscore ≥1 and a centrally assessed endoscopic subscore ≥2 at screening.
  3. Has evidence of UC extending proximally to the rectum [≥15 centimeter (cm) of involved colon].
  4. Participants with extensive colitis or pancolitis of >8 years duration or left sided colitis >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial screening visit.
  5. Participants with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factors must be up to date on colorectal cancer surveillance.
  6. Has demonstrated an inadequate response to, loss of response to, or intolerance to at least 1, but no more than 2 TNFα antagonists. Determination of inadequate response, loss of response, or intolerance is based upon investigator's clinical judgment. Participants who discontinued TNFα antagonist therapy for reasons other than failure or intolerance (eg, pregnancy) may be eligible after discussion with the medical monitor.

Note: After the interim analysis, participants with inadequate response, loss of response, or intolerance to conventional UC therapy per standard of care treatment without prior exposure to biologics may be enrolled if deemed appropriate. Determination of inadequate response, loss of response, or intolerance is based upon investigator's clinical judgment. Participants who discontinued biologics for reasons other than failure or intolerance (eg, pregnancy) may be eligible after discussion with the Medical Monitor. If using corticosteroids must be on a stable dose of oral corticosteroids up to a maximum of 40 mg daily of prednisone or 9 mg daily of budesonide, or equivalent for at least 2 weeks prior to screening endoscopy and must be willing to follow a mandatory taper of corticosteroids.

Exclusion Criteria:

Gastrointestinal Exclusion criteria:

  1. Has any of the following UC-related complications:

    1. Acute severe UC.
    2. The participant has had extensive colonic resection, subtotal or total colectomy.
    3. The participant has clinical evidence of abdominal abscess or toxic megacolon.
    4. The participant has an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
    5. Short bowel syndrome.
  2. Has Crohn's colitis, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug (NSAID) induced colitis, idiopathic colitis (i.e, colitis not consistent with UC), radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption. Participants with a history of colonic mucosal dysplasia are also excluded.

  3. Has uncontrolled primary sclerosing cholangitis.

Infectious Disease Exclusion Criteria:

  1. Has any evidence of an active systemic infection during screening. Participants with nonsystemic infections (eg, active fungal infection of nail beds) may be eligible, if in the opinion of the investigator, inclusion of the participant will not interfere with the collection or interpretation of study results and poses no risk to the participant.

  2. Has active or latent tuberculosis (TB), regardless of treatment history, as evidenced by any of the following:

    1. History of TB.
    2. A diagnostic TB test performed during screening that is positive, as defined by:

    i. A positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests or ii. A tuberculin skin test reaction ≥10 mm (≥5 mm in participants receiving the equivalent of >15 mg daily prednisone).

  3. A positive test for hepatitis B virus (HBV).

  4. A positive test for hepatitis C virus (HCV).

  5. Evidence of, or treatment for, Clostridium difficile infection or other intestinal pathogen during screening. Participants who test positive for C. difficile or other intestinal pathogens at screening and receive treatment may be enrolled or rescreened (if required) following confirmation of infection resolution.

  6. Evidence of active Cytomegalovirus (CMV) infection at screening.

Medication exclusion criteria:

  1. Has received immunomodulators (eg, 6-mercaptopurine, azathioprine, and methotrexate) within 4 weeks prior to first dose or immunosuppressants (eg, cyclosporine, tacrolimus) within 8 weeks prior to first dose.

  2. Any medicinal product, herbal medication, or natural health product which might interfere with cytochrome P450 genotype 3A4 (CYP3A4) within 2 weeks prior to enrollment, except for any CYP3A4 modulator used to treat a C. difficile or an intestinal pathogen infection at screening.

  3. Has received any of the following medical therapies for UC:

    1. IV antibiotics within 8 weeks prior to enrollment.
    2. Any rectal therapy for treatment of UC within 2 weeks prior to screening endoscopy.
    3. Chronic NSAID use defined as daily use for >2 consecutive weeks (Note: occasional use [<2 consecutive weeks] of NSAIDs and acetaminophen [<100 mg daily] for headache, arthritis, myalgias, or menstrual cramps and chronic low dose aspirin use [81-162.5 mg daily] for cardiovascular prophylaxis are permitted).
  4. Has received a live vaccine within 4 weeks prior to first dose.

General Exclusion Criteria:

  1. Has any of the following cardiovascular or thrombotic conditions:

    1. Recent (within past 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting.
    2. Recent (within past 6 months) moderate to severe congestive heart failure (New York Heart Association class III or IV).
    3. Prior history of thrombotic events, including deep vein thrombosis and pulmonary embolism.
    4. Known inherited conditions that predispose to hypercoagulability.
  2. History of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.

  3. A surgical procedure requiring general anesthesia within 3 months prior to screening or is planning to undergo major surgery during the study period.

  4. Any investigational procedure ≤4 weeks prior to screening that, in the investigator's opinion, may interfere with interpretation of study results.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Vedolizumab 300 mg + Tofacitinib 10 mg

Participants will receive Vedolizumab 300 mg, intravenous (IV) infusion, at Week 0, Week 2 and Week 6 along with Tofacitinib 10 mg, tablets, orally, twice daily from Week 0 to Week 8. Participants with clinical response at Week 8 will transition to receive vedolizumab 300 mg IV infusion every 8 weeks (Q8W) through Week 46.

Vedolizumab IV infusions

Altri nomi:
  • Entyvio
  • MLN0002

Tofacitinib Tablets

Altri nomi:
  • Xeljanz
  • CP-690
  • CP-550

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo Score
Lasso di tempo: At Week 8

Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a Physician's Global Index (PGA) and Mayo endoscopic findings (MES). Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Achieving Clinical Remission at Week 52 Based on Complete Mayo Score
Lasso di tempo: At Week 52

Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants Achieving Clinical Remission at Weeks 8, 14, and 26 Based on Partial Mayo Score
Lasso di tempo: At Weeks 8, 14 and 26

Clinical remission based on complete Mayo Score is where a participant achieves partial Mayo Score ≤2 points with no individual subscore >1. Partial Mayo Score consists of 3 variables of the Mayo Clinic Score: stool frequency, rectal bleeding and PGA. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease. These scores are summed to give a total score range of 0 to 9 where higher scores indicate maximum disease activity.

At Weeks 8, 14 and 26
Percentage of Participants Achieving Clinical Response at Weeks 2, 6, 8, 14, 26 and 52 Based on Complete or Partial Mayo Score
Lasso di tempo: At Weeks 2, 6, 8, 14, 26, and 52

Clinical response based on complete Mayo Score is where a participant achieves a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline or a partial Mayo score of ≥2 points and ≥25% from baseline, if the complete Mayo score was not performed at the visit with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Weeks 2, 6, 8, 14, 26, and 52
Percentage of Participants Achieving Clinical Remission at Week 8 and Week 52 Based on Modified Mayo Score
Lasso di tempo: At Weeks 8 and 52

Clinical remission based on modified Mayo Score is where a participant achieves component modified Mayo score of ≤2 with modified MES ≤1, rectal bleeding = 0, and stool frequency ≤1. Modified Mayo Score consists of 3 variables: stool frequency, rectal bleeding and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease. These scores are summed to give a total score range of 0 to 9 where higher scores indicate maximum disease activity.

At Weeks 8 and 52
Percentage of Participants With Endoscopic Improvement at Week 8 and Week 52 Based on Modified Mayo Endoscopic Subscore (MMES)
Lasso di tempo: At Weeks 8 and 52

Endoscopic improvement based on modified mayo endoscopic score is where participants achieve MMES ≤1 point. The subscale is graded from 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher scores indicate more severe disease.

At Weeks 8 and 52
Percentage of Participants With Durable Clinical Remission at Week 8 and Week 52
Lasso di tempo: At Week 8 and Week 52

Durable clinical remission is defined as the clinical remission at Week 8 and Week 52. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Weeks 8 and 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8 and Week 52
Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 8
Lasso di tempo: At Week 8

Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 8
Lasso di tempo: At Week 8

Corticosteroid-free clinical remission is where a participant achieves corticosteroid-free clinical remission at Week 8. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 52
Lasso di tempo: At Week 52

Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 52
Lasso di tempo: At Week 52

Corticosteroid-free clinical remission is where a participant achieves corticosteroid-free clinical remission at Week 52, and was off corticosteroids at least 3 months prior to Week 52. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants Achieving Clinical Response at Week 8
Lasso di tempo: At Week 8

Clinical response based on complete Mayo Score is where a participant achieves a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants With Endoscopic Improvement at Week 52
Lasso di tempo: At Week 52

Endoscopic improvement based on modified mayo score is where participants achieve MMES ≤1 point. The subscale is graded from 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher scores indicate more severe disease.

At Week 52
Percentage of Participants With Histological Remission Based on Geboes Score at Week 52
Lasso di tempo: At Week 52

Histological remission is defined as Geboes score <2 at Week 52. The Geboes score is a histological grading system for assessing histological disease activity in UC. The Geboes score evaluates 7 histological features. It consists of 6 grades (0-6). Each of the grades is divided into subgrades, based on the severity of tissue abnormalities or the extent of inflammatory cell infiltration. The Geboes score ranges from 0.0 to 5.4, and higher grades are indicative of more severe disease activity.

At Week 52
Change in C-Reactive Protein Levels (CRP) From Baseline
Lasso di tempo: Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52

CRP is a useful marker of inflammation in participants with inflammatory bowel disease (IBD). In participants with UC, elevated CRP has been associated with severe clinical activity.

Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
Change in Fecal Calprotectin Concentrations From Baseline
Lasso di tempo: Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52

Fecal calprotectin is a biomarker for intestinal inflammatory activity.

Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline
Lasso di tempo: At Weeks 8, 26 and 52

The IBDQ is an instrument used to assess quality of life in adult participants with inflammatory bowel disease (IBD). It includes 32 questions on 4 domains of Health-Related Quality-of-Life (HRQOL): Bowel Systems (10 items), Emotional Function (12 items), Social Function (5 items), and Systemic Function (5 items). Participants are asked to recall symptoms and quality of life from the last 2 weeks and rate each item on a 7-point Likert scale (1=worst to 7=best). A total IBDQ score is calculated by summing the scores from each domain; the total IBDQ score ranges from 32 to 224, with lower scores reflecting worse HRQOL. A positive change from Baseline indicates improvement.

At Weeks 8, 26 and 52
Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline
Lasso di tempo: At Weeks 8, 26 and 52

The FACIT-F is a validated, 13-item questionnaire to assess fatigue in participants with a variety of chronic illnesses, including participants with IBD. Items are rated on a 5-point Likert scale and the total score ranges from 0 to 52 with lower scores representing greater fatigue.

At Weeks 8, 26 and 52
Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
Lasso di tempo: Up to 76 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention.

Up to 76 weeks
Number of Participants With Clinically Significant Change in Vital Signs From Baseline
Lasso di tempo: Up to 76 weeks

Vital signs will include body temperature, respiratory rate, blood pressure (resting more than 5 minutes), and pulse (resting more than 5 minutes).

Up to 76 weeks
Number of Participants With Clinically Significant Physical Examination Findings
Lasso di tempo: At Baseline and From Week 14 to Week 72

A baseline physical examination (defined as the assessment before first dose of study medication) will consist of the following body systems: general appearance; HEENT (head, eyes, ears, nose, and throat); cardiovascular system; respiratory system; gastrointestinal system; dermatologic system; extremities; musculoskeletal system; nervous system; lymph nodes; and other. All subsequent physical examinations will assess clinically significant changes from the assessment prior to first dose examination.

At Baseline and From Week 14 to Week 72
Number of Participants With Markedly Abnormal Laboratory Values
Lasso di tempo: Up to 76 weeks

Standard laboratory tests will include clinical chemistry, hematology, coagulation and urinalysis.

Up to 76 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Study Director, Takeda

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 giugno 2024

Completamento primario (Stimato)

9 luglio 2027

Completamento dello studio (Stimato)

9 luglio 2027

Date di iscrizione allo studio

Primo inviato

18 ottobre 2023

Primo inviato che soddisfa i criteri di controllo qualità

18 ottobre 2023

Primo Inserito (Effettivo)

23 ottobre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

26 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Criteri di accesso alla condivisione IPD

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi